NASDAQ:REGN Lawsuit Notice: Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Should Contact the Shareholders Foundation
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...
US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Investors who lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact Levi & Korsinsky about pending Class Action - REGN
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want ...
Morningstar2d
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman
TD Cowen recently lowered its price target for Regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for EYLEA®, a key product. The firm pointed to ...
Managed Healthcare Executive13d
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
MarketBeat on MSN4d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...
Investing5d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.
Macau Business1d
REGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses...
Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, March 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law ...
Pharmaceutical Technology13d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
In 2024, it became Regeneron’s top-selling product, beating its blockbuster eye franchise Eylea (aflibercept). Give your ...
Investing5d
Regeneron's SWOT analysis: biotech stock faces eylea challenges, pipeline promise
Regeneron Pharmaceuticals (NASDAQ:REGN), a leading biotechnology company with a market capitalization of $77 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...